Drug Profile
Grass pollen allergy sublingual immunotherapy - ALK-Abello
Alternative Names: Oralgen GrasspollenLatest Information Update: 20 Jun 2014
Price :
$50
*
At a glance
- Originator Fornix BioSciences
- Developer ALK-Abello
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Seasonal allergic rhinitis
Most Recent Events
- 05 Apr 2011 Suspended - Preregistration for Seasonal allergic rhinitis in Netherlands (Sublingual)
- 01 Jul 2010 ALK Abello acquires Artu Biologicals
- 29 Apr 2010 Fornix completes enrolment in its phase III trial for Seasonal allergic rhinitis in Belgium, France, Germany, the Netherlands, Poland and United Kingdom